INTRODUCTION 72
Prostate cancer is the most common non-cutaneous cancer and the second leading cause of 73 death in US men. 1 Despite widespread early responses to androgen deprivation therapy (ADT), the 74 primary treatment for advanced and metastatic prostate cancer, a subset of tumors almost invariably 75 progress to castration-resistant prostate cancer (CRPC) . Although serum androgens are low in men with 76 CRPC, tumor androgens in men on ADT can be sufficient to activate the AR, and a key source of 77 intracellular androgen is de novo steroidogenesis from intratumoral cholesterol. 2-4 78 A number of epidemiological studies found a link between higher serum cholesterol and 79 increased risk of advanced prostate cancer and/or progression. 3, 5, 6 Furthermore, mounting evidence 80 supports an inverse association of the cholesterol-lowering statins with advanced and lethal prostate 81 cancer risk. 7 Among men starting ADT, one study found that statin users had delayed time to CRPC. 8 82 Moreover, in vitro experiments showed that statins inhibited uptake of testosterone precursor 83 dehydroepiandrosterone sulfate by competitively binding transporter SLCO2B1. 8 A large observational 84 study reported that statin use alongside ADT was associated with reduced prostate cancer-specific and all-85 cause mortality. 9 Collectively, these data suggest the potential of targeting cholesterol homeostasis at the 86 time of ADT to improve outcomes. 87
Despite strong biological rationale supporting a potential role for high cholesterol in CRPC, 88 only one epidemiological study has examined this to date. 10 The aim of our study was to examine whether 89 lipid levels prior to ADT were associated with CRPC and metastasis risk after ADT. To test this, we used 90 data from a retrospective cohort of prostate cancer patients in the Shared Equal Access Regional Cancer 91 Hospital (SEARCH) database who received post-operative ADT without known metastatic disease. Our 92 primary hypothesis was that elevated cholesterol would be associated with increased CRPC risk. 93 94
MATERIALS AND METHODS 95

Study sample 96
After obtaining Institutional Review Board approval, data from patients undergoing radical prostatectomy 97 (RP; n=7,811) from 1982-2017 at eight Veterans Administration (VA) Medical Centers were combined 98 into the SEARCH database. 11 SEARCH does not include patients treated with preoperative ADT or 99 radiation therapy. Given our goal to understand if serum lipids at ADT were associated with CRPC or 100 metastasis risk, we excluded patients who never received ADT (n=6, 466) . As illustrated in 101
Supplementary Figure 1 , we excluded men who started statins before ADT, for a more accurate measure 102 of serum cholesterol (n=653). Of 692 non-statin users who started ADT, we excluded patients with 103 missing serum lipids (n=320), missing PSA at ADT (n=36), patients with metastases by the time of ADT 104 (n=27), missing race (n=3), and missing pathology results (n=4), resulting in 302 men. 105
106
Exposure assessment and definitions 107
Fasting serum lipids (total cholesterol, LDL, HDL and TG) measured within two years prior to ADT were 108 abstracted from VA computerized medical records. The VA Informatics and Computing Infrastructure 109 (VINCI) enabled more complete abstraction of lipid data from medical records after 2000. As such, men 110 excluded due to missing lipids had less recent year of ADT ( Supplementary Table 1 ). In addition, these 111 men tended to be older at ADT, were less likely to be black, had higher PSA at surgery and ADT, and 112
were more likely to have received radiation. For men with available lipid data, recommended cut-offs for 113 normal vs. abnormal serum levels (all in mg/dl) were selected based on National Cholesterol Education 114 Program (NCEP)-Adult Treatment Panel (ATP) III guidelines. 12 115 116
Follow-up and outcome ascertainment 117
Follow-up protocols were at the discretion of treating physicians. Pre-ADT PSA doubling time (PSADT) 118 was calculated according to Prostate Specific Antigen Working Group guidelines. 13 CRPC (primary 119 outcome) was defined using Prostate Cancer Working Group Two criteria. 14 Imaging reports (bone scan, 120 magnetic resonance imaging, computed tomography, x-ray) after surgery were assessed by trained 121 personnel to determine the development of metastases (secondary outcome).
123
Statistical analysis 124
The characteristics of men excluded due to pre-ADT statin use are presented in 125 Supplementary Table 2 . Excluded men were slightly older than those included in our analysis, with higher 126 BMI and longer time between surgery and start of ADT. In addition, excluded men had lower total 127 cholesterol, LDL and HDL but higher triglycerides. Pathological characteristics did not differ between 128 excluded and included men. 129
In line with our primary hypothesis, analysis of total cholesterol was considered primary, 130 while analyses of LDL, HDL and TG were considered secondary. Demographic, clinical and pathologic 131 differences between patients with normal vs. abnormal total cholesterol (<200 vs. ≥200 mg/dl) were 132 examined using descriptive statistics. ADT, and PSADT (<9 months, ≥9 months, unknown). Selected covariates are listed in Table footnotes. In 142 sensitivity analysis, given the potential role for obesity in CRPC, 15 we forced BMI into our models and 143 though this made estimates less precise, it did not appreciably change our results. In secondary analysis 144 using the same approach as described for total cholesterol, we tested associations between LDL, HDL and 145 TG and CRPC risk. Analyses were repeated for metastases, treated as a secondary outcome. Further 146 secondary analyses were conducted among men who never took a statin after ADT. Race-stratified 147 analyses showed similar findings in black and white men.
Statistical analyses were conducted using STATA version 13.1 (Stata Corp., College Station, 149 TX, USA). Statistical significance was two-sided with p<0.05. 150
151
RESULTS
152
Patient characteristics 153
Of 302 men, 83 (27%) had elevated cholesterol (≥200 mg/dl) ( Table 1) . Men with elevated cholesterol 154 had earlier years of surgery (2007 vs. 2011, p=0 .004) and longer follow-up (82.5 vs 60.2 months; 155 p=0.035). Men with normal cholesterol were more likely to have had radiation therapy than patients with 156 elevated cholesterol (74% vs. 58%, p=0.005). There were no significant differences between age, race, 157 PSA or pathological tumor features between total cholesterol groups. Men with elevated cholesterol also 158 had higher LDL, higher HDL, and higher TG (all p≤0.009). Patients with normal total cholesterol were 159 less likely to start statins after ADT (33% vs. 61%, p<0.001). 160 161
Serum lipids and CRPC 162
During a median follow-up of 61 months (IQR 32-108), 42 patients developed CRPC. Kaplan-Meier plots 163 showed similar time to CRPC between men with normal vs. abnormal total serum cholesterol (Figure 1 ; 164 log-rank, p=0.61), and there was no association between total cholesterol and CRPC risk on multivariable 165 analysis ( Table 2) . Similarly, in secondary analyses, we found no significant associations between LDL 166 or TG levels and CRPC risk (Table 2) . However, relative to high HDL (≥40 mg/dL), low HDL (<40 167 mg/dL) was suggestively associated with increased risk of CRPC (multivariable HR 1.86, 95%CI 0.99-168 3.48, p=0.053). 169 170 Among 178 men who never took a statin while on ADT, total cholesterol and LDL remained unassociated 171 with CRPC risk (Table 3) . However, on multivariable analysis, higher TG levels as a continuous variable 172
were associated with increased risk of CRPC (HR 1.09, 95%CI 1.02-1.17, p=0.010). Similar to the overall 173 analysis, there was an increased risk of CRPC among patients with HDL <40 mg/dL who did not start a 174 statin after ADT (multivariable HR 3.64, 95%CI 1.45-9.17, p=0.006). 175 176
Serum lipids and metastases 177
During a median follow-up of 64 months (IQR 33-112), 44 patients developed metastases. There was no 178 association between total cholesterol, LDL or TG levels and risk of developing metastases after ADT 179 (Table 4 ). Relative to patients with high HDL, those with low HDL had increased risk of metastasis 180 (multivariable HR 2.02, 95% CI 1.11-3.70, p=0.021). 181 182 Among men who did not start a statin after ADT, there was no association between total cholesterol or 183 LDL and risk of metastasis after ADT ( Table 5) . When treated as a continuous variable, higher TG levels 184
were positively associated with metastasis risk (HR 1.07, 95%CI 1.01-1.13, p=0.027), though no 185 significant association was seen for categorical TG levels. Similar to the overall analysis, low HDL was 186 associated with increased risk of metastasis among men who did not start statins after ADT (multivariable 187 HR 2.64, 95%CI 1.11-6.29, p=0.028). 188
189
DISCUSSION 190
Using data from a retrospective cohort of RP patients subsequently treated with ADT for non-191 metastatic disease, we found no associations between serum cholesterol or LDL and risk of developing 192 either CRPC or metastases. However, low HDL (<40mg/dl) was significantly associated with increased 193 metastases risk and suggestively associated with increased CRPC risk, with stronger associations among 194 men who remained statin non-users throughout follow-up. High TG was also moderately but significantly 195 associated with increased CRPC and metastasis risk, but only in men who remained statin non-users 196 throughout follow-up. These data suggest that low HDL and high TG may have a role in prostate cancer 197 progression. Further investigations are required to better understand dyslipidemia at ADT as a risk factor 198 for CRPC and/or metastases.
We previously reported that elevated serum TG at RP was associated with increased risk of PSA 200 recurrence, while higher total cholesterol and lower HDL were associated with increased risk of 201 recurrence only among men with dyslipidemia. 16 Others have shown no relationship between serum 202 cholesterol and PSA recurrence after surgery, 17 or even an inverse relationship. 18, 19 However, potential 203 factors influencing progression to CRPC may differ from those affecting PSA recurrence. Specifically, a 204 key mechanism leading to CRPC development is de novo steroidogenesis from intratumoral cholesterol. Contrary to our hypothesis, we found no association between serum cholesterol, LDL, or TG 213 levels and CRPC or metastasis risk among all men. Nuances between serum vs. tumor cholesterol may 214 underlie our null findings. Specifically, strong data support the importance of altered tumor cholesterol 215 metabolism in prostate cancer progression. For example, an epidemiological study showed that high 216 tumor gene expression of SQLE, the second rate-limiting enzyme in cholesterol biosynthesis, was 217 associated with increased lethal prostate cancer risk. 21 Recently, our group reported that loss of the p450 218 sterol hydroxylase, CYP27A1, was common in prostate cancer and that restoration of CYP27A1 or its 219 metabolic end-product 27-hydroxycholesterol reduced intracellular cholesterol accumulation and 220 decreased prostate cancer growth in vitro and in vivo. 22 These data provide evidence that altered 221 cholesterol tumor metabolism may drive lethal prostate cancer and that reducing intratumoral cholesterol 222 could impair prostate cancer growth. However, we found no link between serum cholesterol and CRPC 223 risk in the present analysis. It is noteworthy that serum and intratumoral cholesterol are not always 224 correlated. In a prior study, lowering serum cholesterol via ezetimibe had no effect on xenograft growth. 23 225
Despite lower serum cholesterol, the ezetimibe group had higher tumor cholesterol and elevated 226 expression of LDL receptor, potentially a mechanism of resistance to serum cholesterol reduction 227 allowing the tumor to continue to accrue sufficient cholesterol. While simply lowering serum cholesterol 228 may be insufficient to block all prostate cancer growth, these data provide further evidence of the key role 229 of cholesterol in prostate cancer biology. As such, our null findings regarding serum cholesterol and 230 CRPC risk do not invalidate the hypothesis that cholesterol is crucial for CRPC, but merely suggest that 231 serum cholesterol may not be crucial for CRPC. 232
Despite our null findings with respect to total cholesterol, our secondary analyses found low HDL 233 was associated with increased metastases risk and suggestively associated with increased CRPC risk, with 234 stronger associations among men who remained non-statin users throughout follow-up. Low HDL is part 235 of the metabolic syndrome (MS), a group of risk factors including high blood pressure, dyslipidemia, high 236 blood sugar and large waist circumference. 24 Thus, it is possible that the association between low HDL 237 and CRPC is mediated via other MS components, although in the present study our results were not 238 substantially altered after stratifying models by median BMI or including BMI as an additional covariate 239 in our models. Finally, a recent report by Sekine et al. showed that high HDL promoted proliferation and 240 migration of androgen-independent prostate cancer cell lines in vitro, 25 which at first glance appears 241 contradictory to our findings. However, the authors demonstrated that prostate cancer cells uptake HDL 242 more efficiently in low androgen environments via higher expression of ABCA1 receptors, which are 243 normally downregulated by intratumoral androgens. 25 More efficient HDL uptake by prostate cancer cells 244 via this mechanism could deplete serum HDL, potentially leading to our observation that low serum HDL 245 is linked with increased CRPC risk. Thus, further studies are required to clarify the complex biology of 246
HDL in the context of CRPC and metastases. 247
Several study limitations should be considered. First, our sample size was small (n=302), 248 particularly when restricting to statin never-users (n=178), potentially increasing the likelihood of false 249 negative findings. We examined men who received ADT for nonmetastatic disease to create a more 250 homogenous group, and this may limit the generalizability of our results. Moreover, as most men who developed metastasis also developed CRPC, we cannot tease apart the potential role of cholesterol on 252 each of these outcomes. Future studies would benefit from a larger sample size and longer follow-up in 253 order to ascertain a greater number of events. Secondly, we assessed serum lipid levels in the 2-year 254 period prior to ADT, but lipid levels may change over time and may be influenced by the growing tumor 26 255 and/or by prostate cancer treatment. 27 As such, the optimal timing for measuring serum lipids to 256 understand their possible association with CRPC and metastasis is unknown. Moreover, in the context of 257 CRPC, it would be ideal to measure intratumoral cholesterol levels in addition to serum cholesterol as 258 tumor biology may be important for understanding prostate cancer cholesterol metabolism. Again, it 259 would be challenging to track changes over time and thus optimal timing would need to be identified. 260
Finally, though SEARCH is racially diverse, it is largely comprised of earlier-stage patients at lower risk 261 of progression, potentially limiting the generalizability of our findings. 262
In conclusion, our analyses showed that total serum cholesterol prior to ADT was not associated 263 with CRPC risk in patients with non-metastatic prostate cancer undergoing ADT after RP. However, 264 serum cholesterol may not always accurately reflect intratumor cholesterol, and it may be essential to 265 measure tumor cholesterol metabolism to better understand the intricacies of cholesterol biology. Lastly, 266 our analyses suggested that HDL and TG levels may be associated with risk of metastases and CRPC 267 after ADT, particularly among men who remained non-statin users throughout follow-up, a point that 268 requires further validation. 
